Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders

Patent Citations (142)

Non-Patent Literature (404)

• “Identified virulence factors of UPEC: Iron Uptake,” http://www.mgc.ac.cn/cgi-bin/VFs/vfs.cgi?Genus=Escherichia&Species=UPEC&Keyword=Iron%20uptake (accessed on Jan. 12, 2006).Applicant
• “MUTAFLOR, The probiotic drug for life!”, http://www.ardeypharm.de/download.php?id=10000, (downloaded on Apr. 16, 2008).Applicant
• “Vion and Memorial Sloan-Kettering Cancer Center Present Data on Tapet's Potential to Enhance Imaging of Solid Tumors” Press Release, Vion Pharmaceuticals, Inc.(2000).Applicant
• (Bernstein, “Mechanisms of Therapeutic Activity for Gallium” Pharmacol. Rev. 50(4): 665-682 (1998).Applicant
• Abdul-Tehrani et al., “Ferritin Mutants of Escherichia coli Are Iron Deficient and Growth Impaired, and fur Mutants are Iron Deficient” J. Bacteriol. 181(5): 1415-1428 (1999).Applicant
• Adonai et al., “Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography,” Proc. Natl. Acad. Sci. USA 99: 3030-3035 (2002).Applicant
• Aguila, “Iron and Transferrin. Research and Therapeutic Applications” Biotecnologia Aplicada 18(1):1-9 (2001).Applicant
• Åkerman et al., “Nanocrystal targeting in vivo” PNAS 99(20): 12617-12621 (2002).Applicant
• Akita et al., “Identification of oligopeptides binding to peritoneal tumors of gastric cancer,” Cancer Sci. 97(10):1075-1081 (2006).Applicant
• Altenhoefer et al., “The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens,” FEMS Immunol. Med. Microbiol. 40(3): 223-9 (2004).Applicant
• Amato et al., “Luminous with Promise” Chem. Eng. News. 84(49):69-73 (2006).Applicant
• Andrews et al., “Bacterial iron homeostasis” FEMS Microbiol. Rev. 27(2-3): 215-237 (2003).Applicant
• Andrews et al., “Overproduction, purification and characterization of the bacterioferritin of Escherichia coli and a C-terminally extended variant,” Eur. J. Biochem. 213: 329-338 (1993).Applicant
• Andrews, “Iron Storage in Bacteria” Adv. Microb. Physiol. 40: 281-351 (1998).Applicant
• Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,” Science 279: 377-380 (1998).Applicant
• Arap et al., “Targeting the prostate for destruction through a vascular address,” PNAS 99:(3) 1527-1531 (2002).Applicant
• Arosio et al., “On Ferritin Heterogeneity” J. Biol. Chem. 253(12): 4451-4458 (1978).Applicant
• Aziz and Munro. “Iron regulates ferritin mRNA translation through a segment of its 5′ untranslated region” Proc. Natl. Acad. Sci. USA 84: 8478-8482 (1987).Applicant
• Backhed, “Host-bacterial mutualism in the human intestine,” Science. 307(5717):1915-20 (2005).Applicant
• Bagg, “Molecular mechanism of regulation of siderophore-mediated iron assimilation,” Microbiol Rev. 51(4):509-18 (1987).Applicant
• Baichoo and Helmann, J., “Recognition of DNA by Fur: a reinterpretation of the Fur box consensus sequence,” Bacteriol. 184(21):5826-32 (2002).Applicant
• Balchoo et al., “Global analysis of the Bacillus subtilis Fur regulon and the iron starvation stimulon” Mol. Microbiol. 45(6):1613-1629 (2002).Applicant
• Balkwill, F., “Chemokine biology in cancer”, Seminars in Immunol., 15: 49-55 (2003).Applicant
• Barzu, et al., “Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier,” Infect. Immun. 64: 1190-1196 (1996).Applicant
• Bereswill et al., “Structural, functional and mutational analysis of the pfr gene encoding a ferritin from Helicobacter pylori” Microbiology. 144 ( Pt 9): 2505-2516 (1998).Applicant
• Bereswill et al., “Regulation of Ferritin-Mediated Cytoplasmic Iron Storage by the Ferric Uptake Regulator Homolog (Fur) of Helicobacter pylori” J. Bacteriol. 182(21):5948-5953 (2000).Applicant
• Bermudes et al., “Live bacteria as anticancer agents and tumor-selective protein delivery vectors,” Current Opinion in Drug Discovery & Development 5(2):194-199 (2002).Applicant
• Bertani et al. “Physical and genetic characterization of the genome of Magnetospirillum magnetotacticum, strain MS-1” Gene 264: 257-263 (2001).Applicant
• Beshara et al., “Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following blous administration using positron emission tomography,” Br. J. Haematol. 104: 288-295 (1999).Applicant
• Beshara et al., “Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography,” Br. J. Haematol. 104: 296-302 (1999).Applicant
• Bessette et al. “Rapid isolation of high-affinity protein binding peptides using bacterial display” Prot. Eng., Design & Sel. 17(10): 731-739 (2004).Applicant
• Bisno et al., “Streptococcal infections of skin and soft tissues,” N. Engl. J. Med. 334(4): 240-245 (1996).Applicant
• Blakemore, “Magnetotactic Bacteria,” Annu. Rev. Microbiol. 36: 217-238 (1982).Applicant
• Blum et al., “Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis,” Infection. 23(4):234-236 (1996).Applicant
• Bou-Abdallah et al., “Iron detoxification properties of Escherichia coli bacterioferritin” J. Biol. Chem. 277(40): 37064-37069 (2002).Applicant
• Boudeau et al., “Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease,” Aliment Pharmacol Ther. 18(1):45-56 (2003).Applicant
• Braun and Braun, “Active transport of iron and siderophore antibiotics” Curr. Opin. Microbiol. 5:194-201 (2002).Applicant
• Braun and Braun, “Iron transport and signaling in Escherichia coli,” FEBS Lett. 529(1): 78-85 (2002).Applicant
• Braun V., “Iron uptake by Escherichia coli,” Biosci 1(8s):1409-1421 (2003).Applicant
• Bremer et al., “Control of Cyclic Chromosome Replication in Escherichia coli” Microbiol. Reviews 55(3):459-475 (1991).Applicant
• Budzikiewicz et al. “Siderophores of the Pseudomonadaceae sensu stricto (Fluorescent and Non-Fluorescent Pseudomonas spp.” Fortschr. Chem. Org. Naturst. 87: 81-237 (2004).Applicant
• Budzikiewicz, “Siderophores of the human pathogenic fluorescent pseudomonads,” Curr Top Med Chem. 1(1):1-6 (2001).Applicant
• Buss et al., “Iron chelators in cancer chemotherapy” Curr Top Med Chem. 4(15):1623-35 (2004).Applicant
• Calonder et al., “Kinetic modeling of 52Fe/52mMn-Citrate at the Blood-Brain Barrier by Positron Emission Tomography,” J. Neurochem. 73: 2047-2055 (1999).Applicant
• Cane et al., “Harnessing the Biosynthetic Code: Combinations, Permutations, and Mutations” Science 282:63-68 (1998).Applicant
• Carniel, “The Yersinia high-pathogenicity island: an iron-uptake island,” Microbes Infect. 3(7):561-9 (2001).Applicant
• Carrillo and Lipman et al., “The Multiple Sequence Alignment Problem in Biology,” SIAM J Applied Math 48:1073-1082 (1988).Applicant
• Carrondo, “Ferritins, iron uptake and storage from the bacterioferritin viewpoint” EMBO J. 22(9):1959-1968 (2003).Applicant
• Certified English translation of abstract for Aksac S., “[Antibody formation against Agrobacterium tumefaciens in patients with various cancers],” Turk Hij Tecr Biyol Derg. 34(1-2):48-51 (1974).Applicant
• Chasteen and Harrison. “Mineralization in Ferritin: An Efficient means of Iron Storage,” J. Struct. Biol. 126(3): 182-194 (1999).Applicant
• Chaston et al., “Potent antitumor activity of novel iron chelators derived from Di-2-Pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation,” Clin. Canc. Res. 10:7365-7374 (2004).Applicant
• Cheadle, E.J. and A.M. Jackson, “Bugs as Drugs for Cancer,” Immunol., 107: 10-19 (2002).Applicant
• Chen and Morse. “Neisseria gonorrhoeae bacterioferritin: structural heterogeneity, involvement in iron storage and protection against oxidative stress” Microbiology. 145(Pt 10): 2967-2975 (1999).Applicant
• Choe et al. “A Possible Relation of the Helicobacter pylori pfr Gene to Iron Deficiency Anemia?” Helicobacter. 6(1): 55-59 (2001).Applicant
• Choi and Lee. “Secretory and extracellular production of recombinant proteins using Escherichia coli,” Appl. Microbiol. Biotechnol. 64: 625-635 (2004).Applicant
• Christensen et al., “Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines,” Cancer Res. 58(6):1238-44 (1998).Applicant
• Clairmont, C. et al., “Enhanced antitumor activity from tumor-targeting Salmonella expressing endostatin,” American Association for Cancer Research: 91st Annual Meeting of the AACR, Apr. 1-5, 2000, 41:732 Abstract #4653 (2000).Applicant
• Clarke et al., “Structural biology of bacterial iron uptake systems,” Current Topics in Medicinal Chemistry 1: 7-30 (2001).Applicant
• Cohen et al., “Ferritin as an Endogenous MRI Reporter for Noninvasive Imaging of Gene Expression in C6 Glioma Tumors,” Neoplasia 7(2): 109-117 (2005).Applicant
• Cole AM, Ganz T., “Human antimicrobial peptides: analysis and application,” Biotechniques. 29(4):822-6, 828, 830-1 (2000).Applicant
• Collins, J. and C. Wust, “Suppression of SV40 tumors after immunization with group A Streptococcus pyogenes and Bordetella pertussis,” Cancer Res. 34(5):932-7 (1974).Applicant
• Compton, J.L. and A.A. Szalay, “Insertion of nonhomologous DNA into the yeast genome mediated by homologous recombination with a cotransforming plasmid,” Mol Gen Genet. 188(1):44-50 (1982).Applicant
• Condeelis, J. and J.E. Segall, “Intravital imaging of cell movement in tumours”, Nat. Rev. Cancer, 3: 921-930 (2003).Applicant
• Contag et al., “Visualizing Gene Expression in Living Mammals Using a Bioluminescent Reporter” Photochemistry and Photobiology 66(4):523-531 (1997).Applicant
• Contag et al., “Photonic detection of bacterial pathogens in living hosts,” Mol. Microbiol. 18: 593-603 (1995).Applicant
• Cornelis and Matthijs., “Diversity of siderophore-mediated iron uptake systems in fluorescent pseudomonads: not only pyoverdines,” Environ. Microbiol. 4(12): 787-798 (2002).Applicant
• Cornelissen CN., “Transferrin-Iron uptake by Gram-Negative Bacteria” Frontiers in Bioscience 8: d836-d847 (2003).Applicant
• Costa et al., “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” Journal of Immunology, 167(4):2379-2387 (2001).Applicant
• Crichton and Ward., “Iron species in iron homeostasis and toxicity,” Analyst. 120(3):693-697 (1995).Applicant
• Crichton et al., “Iron transport and storage” Eur. J. Biochem. 164:485-506 (1987).Applicant
• Crosa and Walsh., “Genetics and assembly line enzymology of siderophore biosynthesis in bacteria,” Microbiol. Mol. Biol. Rev. 66(2): 223-249 (2002).Applicant
• Crosa JH., “ Genetics and molecular biology of siderophore-mediated iron transport in bacteria,” Microbiol. Rev. 53(4): 517-30 (1989).Applicant
• Crosa, “Signal transduction and transcriptional and posttranscriptional control of iron-regulated genes in bacteria,” Microbiol Mol Biol Rev. 61(3):319-36 (1997).Applicant
• Cross et al., “Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria,” FEMS Immunol. Med. Microbiol. 42:173 (2004).Applicant
• Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success” Science 270:404-410 (1995).Applicant
• Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. “In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors,” Science. 256(5063):1550-2 (1992).Applicant
• de Boer et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,” PNAS 80, 21 (1983).Applicant
• de Wet et al., “Firefly Luciferase Gene: Structure and Expression in Mammalian Cells,” Mol. Cell. Biol. 7: 725-737 (1987).Applicant
• Devereux et al., “A comprehensive set of sequence analysis programs for the VAX,” Nucleic Acids Research 12(1): 387-95 (1984).Applicant
• Dietrich et al., “Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes,” Nat Biotechnol. 16(2):181-5 (1998).Applicant
• Ding et al., “Zinc-dependent dimers observed in crystals of human endostatin,” Proc. Natl. Acad. Sci. USA 95:10443-10448 (1998).Applicant
• Dobrindt et al., “Analysis of genome plasticity in pathogenic and commensal Escherichia coli isolates by use of DNA arrays” J. Bacteriol. 185(6):1831-1840 (2003).Applicant
• Drechsel and Jung, “Peptide Siderophores” J. Pept. Sci. 4(3): 147-181 (1998).Applicant
• Dunn et al., “Cancer immunoediting: from immunosurveillance to tumor escape.,” Nat Immunol. 3(11):991-8 (2002).Applicant
• Escher et al., “Bacterial luciferase αβ fusion protein is fully active as a monomer and highly sensitive in vivo to elevated temperature,” Proc Natl Acad Sci U S A. 86(17):6528-32 (1989).Applicant
• Escolar et al., “Evidence of an Unusually long Operator for the Fur repressor in the Aerobactin Promoter of Escherichia coli” J. Biol. Chem. 275(32):24709-24714 (2000).Applicant
• Falkner and Moss, “Transient dominant selection of recombinant vaccinia viruses,” J. Virol. 64:3108-2111 (1990).Applicant
• Faraldo-Gomez and Sansom, “Acquisition of siderophores in gram-negative bacteria,” Nat. Rev. Mol. Cell. Biol. 4(2): 105-116 (2003).Applicant
• Farkas-Himsley et al., “The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1,” Proc Natl Acad Sci U S A. 92(15):6996-7000 (1995).Applicant
• Fatyol, K and A.A. Szalay, “The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1I (HIF-1I ) and inhibits HIF-1-mediated transcription,” J Biol Chem. 276(30):28421-28429 (2001).Applicant
• Ferguson and Deisenhofer, “TonB-dependent receptors-structural perspectives,” Biochim. Biophys. Acta. 1565(2): 318-332 (2002).Applicant
• Fernández-Piñas, F. and C.P. Wolk, “Expresssion of luxCD-E in Anabaena sp. can replace the use of exogenous aldehyde for in vivo localization of transcription by luxAB,”Gene 150:169-174 (1994).Applicant
• Forbes Lab Website, www.ecs.umass.edu/che/faculty/forbes.html, accessed on Feb. 6, 2006.Applicant
• Forbes et al., “Sparse Initial Entrapment of Systematically Injected Salmonella typhimurium Leads to Heterogenous Accumulation within Tumors,” Cancer Res., 63: 5188-5193 (2003).Applicant
• Fox et al., Erratum to “Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia,” Gene Therapy, 3(8):741 (1996).Applicant
• Fox et al., “Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia,” Gene Therapy, 3(2):173-178, (1996).Applicant
• Francis et al., “Monitoring bioluminescent Staphyloccus aureus infections in living mice using a novel luxABCDE construct,” Infection and Immunity 68(6): 3594-3600 (2000).Applicant
• Francisco et al., “Transport and anchoring of beta-lactamase to the external surface of Escherichia coli,” PNAS USA 89: 2713-2717 (1992).Applicant
• Funovics et al., “MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents” Magnetic Resonance Imaging 22: 843-850 (2004).Applicant
• Gafvelin, “Topological rules for membrane protein assembly in eukaryotic cells,” J Biol Chem. 272(10):6119-27 (1997).Applicant
• Gautam et al., “Delivery systems for pulmonary gene therapy,” American Journal of Respiratory Medicine, 1(1):35-46, (2002).Applicant
• Gelfand et al., “Infections in burn patients: a paradigm for cutaneous infection in the patient as risk” Am. J. Med. 76(5A):158-165 (1984).Applicant
• Genove G, Demarco U, Xu H, Goins WF, Ahrens ET. “A new transgene reporter for in vivo magnetic resonance imaging” Nat Med. 11(4):450-454 (2005).Applicant
• Georgiou et al., “Display of beta-lactamase on the Escherichia coli surface: outer membrane phenotypes conferred by Lpp′-OmpA′-beta-lactamase fusions,” Protein Eng. 9: 239-247 (1996).Applicant
• Giacomin, L.T. and A.A. Szalay, “Expression of a PALI promoter luciferase gene function in Arabidopsis thaliana in response to infection by phytopathogenic bacteria,” Plant Sci. 116: 59-72 (1996).Applicant
• Gill and Guarner, “Probiotics and human health: a clinical perspective,” Postgrad Med J. 80(947):516-26 (2004).Applicant
• Grace et al., “Production of recombinant human apoferritin heteromers” Arch Biochem Biophys. 384(1): 116-122 (2000).Applicant
• Gray, J.W., “Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors”, Cancer Cell, 4(1): 4-6 (2003).Applicant
• Green et al., “Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase” Clin. Canc. Res. 7:3574-3579 (2001).Applicant
• Greer III, L.F. and A.A. Szalay, “Imaging of light emission from the expression of luciferases in living cells and organisms: a review,” Luminescence. 17(1):43-74 (2002).Applicant
• Gribskov et al., “Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins,” Nucl. Acids Res. 14:6745-6763 (1986).Applicant
• Grossman et al., “Unification of the ferritin family of proteins” PNAS USA 89: 2419-2423 (1992).Applicant
• Grozdanov et al., “Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917,” J Bacteriol. 186(16): 5432-5441 (2004).Applicant
• Gruenewald et al., “In vivo production of Artificial Nonribosomal Peptide Products in the Heterologous Host Escherichia coli” Appl. Environ. Microbiol. 70(6):3282-3291 (2004).Applicant
• Guo et al. “Suppression of cell growth by heavy chain ferritin” Biochem Biophys Res Commun. 242(1): 39-45 (1998).Applicant
• Gura, T., “Systems for identifying new drugs are often faulty,” Science, 278:1041-1042, (1997).Applicant
• Hale et al., “Characterization of virulence plasmids and plasmid-associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and Escherichia coli,” Infect Immun. 40(1): 340-350 (1983).Applicant
• Hall et al., “In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme,” J Neurosurg. 76(5):838-44 (1992).Applicant
• Hall et al., “In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma,” Neurosurgery 34(4):649-55; discussion 655-6 (1994).Applicant
• Hantke et al., “Salmochelins, siderophores of Salmonella enterica and uropathogenic Escherichia coli strains, are recognized by the outer membrane receptor IroN,” Proc Natl Acad Sci U S A. 100(7):3677-82. Epub (2003).Applicant
• Hatta, “Antitumor Mechanisms of Eubacterium lentum and its Components,” Asian Pacific Journal of Allergy and Immunology 13: 129-137 (1995).Applicant
• Henderson, “Vibrio cholerae iron transport systems: roles of heme and siderophore iron transport in virulence and identification of a gene associated with multiple iron transport systems,” Infect Immun. 62(11):5120-5 (1994).Applicant
• Hill et al., “SirR, a novel iron-dependent repressor in Staphylococcus epidermidis,” Infect Immun. 66(9): 4123-4129 (1998).Applicant
• Hirosue et al. “Characterization of Two Genes Encoding Ferritin-Like Protein in Actinobacillus actinomycetemcomitans” Microbiol. Immunol. 45(10): 721-727 (2001).Applicant
• Hockertz, “Immunomodulating effect of killed, apathogenic Escherichia coli, strain Nissle 1917, on the macrophage system,” Arzneimittelforschung. 41(10):1108-12 (1991).Applicant
• Holland, “Translocation of bacterial proteins-an overview” Biochimica et biophysica acta 1694:5-16 (2004).Applicant
• Hong et al., “The use of bacterial spore formers as probiotics,” FEMS Microbiol Rev. 29(4):813-35 Epub (2005).Applicant
• Howard et al., “Iron gathering by zoopathogenic fungi” FEMS Immunology Med. Microbiol. 40:95-100 (2004).Applicant
• Hudson et al. “Overproduction, purification and characterization of the Escherichia coli ferritin” Eur. J. Biochem. 218: 985-995 (1993).Applicant
• Ianaro et al., “Expression of TGF-β in attenuated Salmonella typhimurium: oral administration leads to the reduction of inflammation, Il-2 and IFN-γ, but enhancement of IL-10, in carrageein-induced oedema in mice,” Immunology 84:8-15 (1995).Applicant
• Ilari et al., “Iron incorporation into Escherichia coli Dps gives rise to a Ferritin-like microcrystalline core” J. Biol. Chem. 277(40): 37619-37623 (2002).Applicant
• Itoh et al., “Formation of an RNA primer for initiation of replication of ColE1 DNA by ribonuclease H” Proc. Natl Acad. Sci. USA 77(5):2450-2454 (1980).Applicant
• Jadvar et al., “Molecular Imaging Update: “Personalized” Imaging for Improved Diagnosis and Treatment Decisions” Highlights of Soc. Nuc. Med. 52nd Ann. Meeting (2005). (www.medscape.com/viewarticle/510976 accessed on Jul. 5, 2007).Applicant
• Jain, R.K. and B.T. Fenton, “Intratumoral Lymphatic Vessels: A Case of Mistaken Identity or Malfunction?”, Journal of the National Cancer Institute, 94(6): 417-421 (2002).Applicant
• Jain, R.K. and N.S. Forbes, “Can engineered bacteria help control cancer?” Proc. Natl. Acad. Sci. USA 98(26): 14748-14750 (2001).Applicant
• Jongbloed et al., “Two minimal Tat translocases in Bacillus” Mol. Microbiol. 54(5):1319-1325 (2004).Applicant
• Kameyama et al., “Bisucaberin, a new siderophore, sensitizing tumor cells to macrophage-mediated cytolysis,” J. Antibiotics 40(12):1664-1670 (1987).Applicant
• Keech et al., “Spectroscopic Studies of Cobalt(II) Binding to Escherichia coli bacterioferritin” 272(1):422-429 (1997).Applicant
• Kelland et al. “Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development” European J. Cancer 40:827-836 (2004).Applicant
• Kemp et al., “Inhibition of Lymphoma Growth In Vivo by Combined treatment with Hydroxyethyl Starch Deferoxamine Conjugate and IgG Monoclonal Antibodies against the Transferrin Receptor” Cancer Res. 55:3817-3824 (1995).Applicant
• Kerbel et al., “Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans” Cancer Biology & Therapy 2:4 suppl. 1, S134-S139 (2003).Applicant
• Kim and Yoo., “Cell surface display of hepatitis B virus surface antigen by using Pseudomonas syringae ice nucleation protein,” Lett. Appl. Microbiol. 29: 292-297 (1999).Applicant
• Kim et al., “Bacterial cell surface display of an enzyme library for selective screening of improved cellulase variants,” Appl. Environ. Microbiol. 66: 788-793 (2000).Applicant
• Kimura et al., “Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration,” Cancer Res. 40(6):2061-8 (1980).Applicant
• Kingsley et al., “Iron supplying systems of Salmonella in diagnosis, epidemiology and infection” FEMS Immunol. Med. Microbiol. 11:257-264 (1995).Applicant
• Kunkle and Schmitt, “Analysis of a DtxR-regulated iron transport and siderophore biosynthesis gene cluster in Corynebacterium diphtheriae,” J Bacteriol. 187(2):422-33 (2005).Applicant
• Klebba PE., “Three paradoxes of ferric enterobactin uptake,” Frontiers in Bioscience 8: s1422-s1436 (2003).Applicant
• Köster W. Res. “ABC transporter-mediated uptake of iron, siderophores, heme and vitamin B12,” Microbiol. 152(3-4): 291-301 (2001).Applicant
• Kozak, M., “Structural features in Eukaryotic mRNAs that modulate the Initiation of Translation,” J. Biol. Chem. 266:19867-19870 (1991).Applicant
• Kozak. “Regulation of Translation in Eukaryotic Systems” Annu. Rev. Cell Biol. 8: 197-225 (1992).Applicant
• Kruis, W., “Review article: antibiotics and probiotics in inflammatory bowel disease,” Aliment. Pharmacol. Ther. 20 (Suppl 4): 75-78 (2004).Applicant
• Kues et al., “Replication of Plasmids in Gram-Negative Bacteria” Microbiol. Reviews 53(4):491-516 (1989).Applicant
• Laakkonen et al., “A tumor-homing peptide with a targeting specificity related to lymphatic vessels,” Nature Medicine 8(7): 751-755 (2002).Applicant
• Lagenaur and Berger, “An anti-HIV microbicide comes alive,” Proc Natl Acad Sci U S A. 102(35):12294-5 Epub (2005).Applicant
• Lamberton et al., “Construction and characterization of a bioluminescent Streptococcus pyogene,” Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence Progress & Current Appications, Stanley, P.E. and L.J. Kricka et al (Eds). World Scientific Publishing Co. Pte. Ltd., pp. 85-88 (2002).Applicant
• Lamberton et al., “Generation and characterization of a bioluminescent Streptococcus pyogenes,” Proceedings of the 12th International Symposium on Bioluminescence & Chemiluminescence: Apr. 5-9, 2002, Robinson College, University of Cambridge, UK, p. 3.22 (2002).Applicant
• Larson et al., “Triumph over mischance: a role for nuclear medicine in gene therapy,” J Nucl Med. 38(8):1230-3 (1997).Applicant
• Lee et al. “Prodrug and antedrug: two diametrical approaches in designing safer drugs,” Arch. Pharm. Res. 25(2): 111-136 (2002).Applicant
• Lee et al., “The lux genes of the luminous bacterial symbiont Photobacterium leiognathi, of the ponyfish,” Eur. J. Biochem. 201: 161-167 (1991).Applicant
• Lee et al., “Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii,” Infect. Immunol. 67: 1511-1516 (1999).Applicant
• Leenders et al., “Blood to brain iron uptake in one Rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol,” J. Neural.Transm.Suppl. 43: 123-132 (1994).Applicant
• Legocki et al., “Bioluminescence in soybean root nodules: Demonstration of a general approach to assay gene expression in vivo by using bacterial luciferase,” Proc. Natl. Acad. Sci 83: 9080-9084 (1986).Applicant
• Lemmon et al., “Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment,” Gene Therapy 4: 791-796 (1997).Applicant
• Lemmon et al., “Anaerobic bacteria as a gene delivery system to tumors,” Proceedings of the 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA Apr. 10-13, 1994, published in: Proc. Am. Cancer Research Assn 35: 374 (1994).Applicant
• Lewin et al. “Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells” Nature Biotechnology 18: 410-414 (2000).Applicant
• Lewis et al., “Comparison of Four 64Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model: Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy,” J. Med. Chem. 42: 1341-1347 (1999).Applicant
• Li et al., “An engineered and assembled fusion protein of antitumor antibiotic lidamycin and scFV antibody directed against type IV collagenase” Yaoxue Xuebao 35(7) 488-91 (Jul. 2000).Applicant
• Li et al., “Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective Inhibitor of angiogenesis and hypoxic tumor growth,” Cancer Gene Therapy 10: 105-111 (2003).Applicant
• Li et al., “Analysis of the Bacillus subtilis S10 ribosomal protein gene cluster identifies two promoters that may be responsible for transcription of the entire 15-kilobase S10-spc-alpha cluster,” J. Bacteriol. 179(22):7046-7054 (1997).Applicant
• Li, W. and C. Li, “Lack of inhibitory effects of Lactic acid bacteria on 1,2-dimethylhydrazine-induced colon tumor,” World J Gastroenterol 9(11):2469-2473 (2003).Applicant
• Lin DC., “Probiotics as functional foods,” Nutr Clin Pract. 18(6):497-506 (2003).Applicant
• Linsalata, “Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats,” In Vivo. 19(6):989-95 (2005).Applicant
• Liu et al., “Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis,” Gene Ther. 9(4):291-6 (2002).Applicant
• Lorenz et al., “Isolation and expression of a cDNA encoding Renilla reniformis luciferase,” PNAS USA 88: 4438-4442 (1991).Applicant
• Louie, A.Y. et al., “In vivo visualization of gene expression using magnetic resonance imaging”, Nature Biotechnology, 18: 321-325 (2000).Applicant
• Love et al., “Radionuclide imaging of Infection,” J Nucl Med Technol. 32(2):47-57; quiz 58-9 (2004).Applicant
• Ma et al., “Bacterioferritin A modulates catalase A (KatA) activity and resistance to hydrogen peroxide in Pseudomonas aeruginosa” J. Bacteriol. 181(12):3730-3742 (1999).Applicant
• Macintyre, “Probiotics: the benefits of bacterial cultures,” Compr Ther. 31(3):181-5 (2005).Applicant
• Maeda et al., “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review”, J. Controlled Release, 65: 271-284 (2000).Applicant
• Martinez et al., “Specific Antibody to Cryptococcus neoformans Glucurunoxylomannan Antagonizes Antifungal Drug Action against Cryptococcal Biofilms in Vitro” J. Infect. Diseases 194:261-266 (2006).Applicant
• Martinez-Govea, “Identification and strain differentiation of Vibrio cholerae by using polyclonal antibodies against outer membrane proteins,” Clin Diagn Lab Immunol. 8(4):768-71 (2001).Applicant
• Masse et al., “A small RNA regulates the expression of genes involved in iron metabolism in Escherichia coli” Proc. Natl. Acad. Sci. 99(7):4620-4625 (2002).Applicant
• Massoud et al., “Molecular imaging in living subjects: seeing fundamental biological processes in a new light”, Genes & Develop. 17:545-580 (2003).Applicant
• McDonald, D.M. and P.L. Choyke, “Imaging of angiogenesis: from microscope to clinic”, Nature Medicine, 9(6): 713-725 (2003).Applicant
• McIntosh et al., “A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats,” Nutr Cancer. 35(2):153-9 (1999).Applicant
• Meighen, E.A. and R.B. Szittner, “Multiple Repetitive Elements and Organization of the lux Operons of Luminescent Terrestrial Bacteria,” J. Bacteriol. 174(16):5371-5381 (1992).Applicant
• Mejare et al., “Selection of cadmium specific hexapeptides and their expression as OmpA fusion proteins in Escherichia coli,” Protein Eng. 11(6):489-94 (1998).Applicant
• Mey et al., “Haem utilization in Vibrio cholerae involves multiple TonB-dependent haem receptors” Mol. Microbiol. 42(3):835-849 (2001).Applicant
• Mills et al., “Genetics and Regulation of Heme Iron Transport in Shigella dysenteriae and Detection of an Analogous System in Escherichia coli O157:H7” J. Bacteriol. 177(11): 3004-3009 (1995).Applicant
• Mills et al., “Identification of shuA, the Gene Encoding the Heme Receptor of Shigella dysenteriae, and Analysis of Invasion and Intracellular Multiplication of a shuA Mutant” Infection and Immunity 65(12):5358-5363 (1997).Applicant
• Milton et al., “Flagellin A is essential for the virulence of Vibrio anguillarum,” J. Bact 178(5):1310-1319 (1996).Applicant
• Moats, et al., “A ‘smart’ magnetic resonance imaging agent that reports on specific enzymatic activity,” Angew. Chem. Int. Ed. Eng., 36(7):726-728, (1997).Applicant
• Modady et al., “Virulence factors of septicemic Escherichia coli strains” Int. J. Med. Microbiol. 295:455-462 (2005).Applicant
• Morinaga et al., “Antitumor Activity and its Properties of Eubacterium lentum,” Jpn. J. Cancer Res. (Gann) 79: 117-124 (1988).Applicant
• Mountz et al. “Technetium-99m NeoTect imaging in vivo of T cells from hCAR transgenic mice,” FASEB J. 16(5):A1211 March Meeting abstract (2002).Applicant
• Mueller, “Layers of mutualism with commensal bacteria protect us from intestinal inflammation,” Gut. 55(2):276-84 (2006).Applicant
• Mutschler et al. “10. Chemotherapy of Malignant Tumors” in: Drug Actions: Basic Principles and Therapeutic Aspects (medpharm (CRC Press), Suttgart, pp. 595-612 (1995).Applicant
• Nagy et al., “Expression of Hemin Receptor Molecule ChuA is Influenced by RfaH in Uropathogenic Escherichia coli Strain 536” Infection and Immunity 69(3):1924-1928 (2001).Applicant
• Nair et al., “Dps protects cells against multiple stresses during stationary phase” J. Bacteriol. 186(13):4192-4198 (2004).Applicant
• NCBI Nucleotide AF188737.Applicant
• NCBI Nucleotide AJ586887.Applicant
• NCBI Nucleotide AJ586888.Applicant
• NCBI Nucleotide AJ586889.Applicant
• Negre, “The siderophore receptor IroN, but not the high-pathogenicity island or the hemin receptor ChuA, contributes to the bacteremic step of Escherichia coli neonatal meningitis,” Infect Immun. 72(2):1216-20 (2004).Applicant
• Neilands JB., “Siderophores: structure and function of microbial iron transport compounds,” J. Biol. Chem. 270(45): 26723-26726 (1995).Applicant
• Neilands JB., “Siderophores of bacteria and fungi,” Microbiol. Sci. 1(1): 9-14 (1984).Applicant
• Neilands, “Siderophores,” Arch Biochem Biophys. 302(1):1-3 (1993).Applicant
• Nibbering et al. “Radiolabelled antimicrobial peptides for imaging of infections: a review,” Nucl Med Commun. 19(12):1117-21 (1998).Applicant
• Ogden et al., “The Escherichia coli L-arabanose operon: Binding sites of the regulatory proteins and a mechanism of positive and negative regulation” Proc. Natl. Acad. Sci. USA 77(6):3346-50.Applicant
• O'Kane et al., “Visualization of Bioluminescence as a Marker of Gene Expression in Rhizobium-Infected Soybean Root Nodules,” J. Plant Mol. Biol. 10: 387-399 (1988).Applicant
• Okeke et al., “Molecular epidemiology of the iron utilization genes of enteroaggregative Escherichia coli,” J Clin Microbiol. 42(1):36-44 (2004).Applicant
• Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,” 1-41 Dec. 7, 1995.Applicant
• Palmer et al. “Export of complex cofactor-containing proteins by the bacterial Tat pathway” Trends in Microbiol. 13(4): 175-180 (2005).Applicant
• Pan et al., “Regression of Established B16F10 Melanoma with a Recombinant Listeria monocytogenes Vaccine,” Cancer Research 59:5264-5269 (1999).Applicant
• Pardal et al., “Applying the principles of stem-cell biology to cancer,” Nature Reviews Cancer, 3: 895-902 (2003).Applicant
• Parish, C.R., “Cancer immunotherapy: The past, the present and the future”, Immunology and Cell Biology, 81: 106-113 (2003).Applicant
• Park et al., “Arginine deiminase: a potential inhibitor of angiogenesis and tumor growth” Br. J. Cancer 89:907-914 (2003).Applicant
• Pasqualini and Ruoslahti, “Organ targeting in vivo using phage display peptide libraries,” Nature 380: 364-366 (1996).Applicant
• Pasqualini et al., “Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis,” Cancer Res. 60: 722-727 (2000).Applicant
• Paterson et al., “The biology of Gram-positive sortase enzymes” Trends Microbiol. 12(2):89-95 (2004).Applicant
• Patzer et al., “The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN” Microbiol. 149:2557-2570 (2003).Applicant
• Pawelek, J.M. et al., “Bacteria as tumour-targeting vectors,” The Lancet Oncology, 4: 548-556 (2003).Applicant
• Payne et al., “Detection, Isolation, and Characterization of Siderophores”, Methods Eznymol. 235:329-344 (1994).Applicant
• Pfeifer et al., “Biosynthesis of Complex Polyketides in a Metabolically Engineered Strain of E. coli” Science 291 (5509):1790-1792 (2001).Applicant
• Pfeifer et al., “Biosynthesis of Polyketides in Heterologous Hosts” Microbiol. Mol. Biol. Rev. 65(1):106-118 (2001).Applicant
• Pfeifer et al., “Biosynthesis of Yersiniabactin, a Complex Polyketide-Nonribosomal Peptide, Using Escherichia coli as a Heterologous Host” Appl. Environm. Microbiol. 69(11):6698-6702 (2003).Applicant
• Pfeifer, A., and I. Verma, “Gene therapy: promises and problems,” Annual Review of Genomics and Human Genetics, 2:177-211, (2001).Applicant
• Pilcher, H., “GM Bug activates cancer drug: Bacteria targets medicine to shrivel mouse tumours,” news @ nature.com, Published online. Apr. 22, 2004; http://www.nature.com/news/2004/040419/ful1/040419-9.html, (accessed on Nov. 18, 2004).Applicant
• Poole and McKay, “Iron acquisition and its control in Pseudomonas aeruginosa: many roads lead to Rome,” Front Biosci. 8: d661-686 (2003).Applicant
• Porkka et al., “A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo,” PNAS 99(11): 7444-7449 (2002).Applicant
• Power, “Regulatory gene control of transcription of the L-arabinose operon in Escherichia coli,” J Biol Chem. 248(22):7806-10 (1973).Applicant
• Prasher et al., “Primary structure of the Aequorea victoris green-fluorescent protein,” Gene 111: 229-233 (1992).Applicant
• Prasher et al., “Sequence Comparison of Complementary DNAs Encoding Aequorin Isotypes,” Biochemistry 26: 1326-1332 (1987).Applicant
• Pulliainen et al. “Dps/Dpr ferritin-like protein: insights into the mechanism of iron incorporation and evidence for a central role in cellular iron homeostasis in Streptococcus suis” Mol. Microbiol. 57(4): 1086-1100 (2005).Applicant
• Qazi, SNA, Counil E, Morrissey J, Rees CED, Cockayne A, Winzer K, Chan WC, Williams P, Hill PJ., “agr expression precedes escape from the endosome of Staphylococcus aureus.” Infection and Immunity: 69(11): 7074-7082 (2001).Applicant
• Quadri LE., “Assembly of aryl-capped siderophores by modular peptide synthetases and polyketide synthases,” Mol. Microbiol. 37(1): 1-12 (2000).Applicant
• Rajotte and Ruoslahti., “Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display,” J. Biol. Chem. 274(17): 11593-11598 (1999).Applicant
• Rao, “Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide,” Proc Natl Acad Sci U S A. 102(34):11993-8. Epub (2005).Applicant
• Ratledge and Dover., “Iron metabolism in pathogenic bacteria,” Annu. Rev. Microbiol. 54: 881-941 (2000).Applicant
• Raymond et al., “Enterobactin: an archetype for microbial iron transport,” PNAS USA. 100(7): 3584-3588 (2003).Applicant
• Reddy et al. “Folate-mediated targeting of therapeutic and imaging agents to cancers,” Crit Rev Ther Drug Carrier Syst. 15(6):587-627 (1998).Applicant
• Rehemtulla, A., et al., “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia, 2(6):491-495, (2000).Applicant
• Reindel et al., “Expression and regulation pattern of ferritin-like DpsA in the archaeon Halobacterium Salinarum,” Biometals. 18(4):387-397 (2005).Applicant
• Riedmann et al., “Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts—a delivery system for the nontypeable Haemophilus influenzae antigen Omp26,” FEMS Immunol Med Microbiol. 37(2-3):185-92 (2003).Applicant
• Rizzo, “An improved cyan fluorescent protein variant useful for FRET,” Nat Biotechnol. 22(4):445-9 (2004).Applicant
• Rocchetta et al., “Validation of a Noninvasive, Real-Time Imaging Technology Using Bioluminescent Escherichia coli in the Neutropenic Mouse Thigh Model of Infection,” Antimicrobial Agents and Chemotherapy 45(1): 129-137 (2001).Applicant
• Rohde and Dyer., “Mechanisms of iron acquisition by the human pathogens Neisseria meningitidis and Neisseria gonorrhoeae,” Frontiers in Bioscience 8: d1186-d1218 (2003).Applicant
• Roosenberg, “Studies and syntheses of siderophores, microbial iron chelators, and analogs as potential drug delivery agents,” Curr Med Chem. 7(2):159-97 (2000).Applicant
• Rothenberg, M.L. et al., “Improving the evaluation of new cancer treatments: challenges and opportunities,” Nat. Rev. Cancer, 3: 303-309 (2003).Applicant
• Rouault and Klausner. “Regulation of iron metabolism in Eukaryotes” Curr. Top. Cell. Reg. 35: 1-19 (1997).Applicant
• Rouault and Klausner, “The impact of oxidative stress on eukaryotic iron metabolism” EXS. 77: 183-197 (1996).Applicant
• Rubanyi et al., “The future of human gene therapy” Molecular Aspects of Medicine 22:113-142 (2001).Applicant
• Saba et al., “Lysogenic Bacteria, Capable of Therapeutic Virus Liberation Subsequent to Tumor Cell Targeting” General Science Journal www.wbabin.net/saba/saba21.htm (2005) (Accessed on Dec. 14, 2005).Applicant
• Sakamoto et al., “Antitumor Effect of Normal Intestinal Microflora on Ehrlich Ascites Tumor,” Jpn. J. Cancer Res. (Gann) 79: 109-116 (1988).Applicant
• Samuelson et al. “Display of proteins on bacteria” J. Biotechnol. 96: 129-154 (2002).Applicant
• Sartor RB., “Probiotic therapy of intestinal inflammation and infections,” Curr. Opin. Gastroenterol. 21(1): 44-50 (2005).Applicant
• Schalk et al., “A new mechanism for membrane iron transport in Pseudomonas aeruginosa,” Biochem. Soc. Trans. 30(4): 702-705 (2002).Applicant
• Schleif, “Regulation of the L-arabinose operon in Escherichia coli,” SGM Symposium 61: 155-168 (2002).Applicant
• Schnetz, Embo J., “Silencing of Escherichia coli bgl promoter by flanking sequence elements,” 14(11):2545-2550 (1995).Applicant
• Schultz et al., “Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo,” J. Microbiol. Methods 61(3): 389-398 (2005).Applicant
• Schultz et al., “Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis,” Clin Diagn Lab Immunol. 11(2):372-8 (2004).Applicant
• Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358 (1979).Applicant
• Schwarze et al., “In vivo protein transduction: delivery of a biologically active protein into the mouse,” Science 285: 1569-1572 (1999).Applicant
• Smith JL. “The Physiological Role of Ferritin-Like Compounds in Bacteria” Crit. Rev. Microbiol. 30(3): 173-185 (2004).Applicant
• Sommerville, “Escherichia coli msbB Gene as a virulence factor and a therapeutic target,” Infection and Immunity. 67(12): 6583-6590 (1999).Applicant
• Spooner et al., “In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug,” Cancer Gene Ther. 7(10):1348-56 (2000).Applicant
• Springer et al., “Bacteria in Cancer Therapy” Microbiology Today 56:113-115 (Aug. 2005).Applicant
• Stehle et al., “Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia”, Critical Reviews in Oncology/Hematology, 26: 77-100 (1997).Applicant
• Stentebjerg-Olesen, “Type 1 fimbriation and phase switching in a natural Escherichia coli fimB null strain, Nissle 1917,” J Bacteriol. 181(24):7470-8 (1999).Applicant
• Stillman et al., “Insights into the Effects on Metal Binding of the Systematic Substitution of Five Key Glutamage Ligands in the Ferritin of Escherichia coli” J. Biol. Chem. 278(28):26275-26286 (2003).Applicant
• Stritzker et al., “Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice” Int J. Med. Microbiol. 297(3):151-162 (2007).Applicant
• Sturm et al., “Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling,” Infect Immun. 73(3):1452-65 (2005).Applicant
• Sudimack et al. “Targeted drug delivery via the folate receptor.” Adv Drug Deliv Rev. 41(2):147-62 (2000).Applicant
• Sui et al., “Cell Cycle-Dependent Antagonistic Interactions between Paclitaxel and gamma-Radiation in Combination Therapy” Clin. Canc. Res. 10:4848-4857 (2004).Applicant
• Sun et al., “Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data” J. Biotech. 117:147 (2005).Applicant
• Suvorov et al., “Physical and genetic chromosomal map of an M type 1 strain of Streptococcus pyogenes,” J. Bacteriol. 178(18): 5546-5549 (1996).Applicant
• Suzuki and Lonnerdal. “Characterization of mammalian receptors for lactoferrin” Biochem Cell Biol. 80(1):75-80 (2002).Applicant
• Suzuki et al., “Management of orbital lymphangioma using intralesional injection of OK-432,” Br. J. Opthalmol. 84(6): 614-617 (2000).Applicant
• Tanaka et al, “Preliminary evaluation of intratumoral injection of a Streptococcus pyrogenes preparation in patients with malignant brain tumors,” Cancer 46(7):1688-94 (1980).Applicant
• Theuer et al., “A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing,” J.Biol.Chem. 267(24): 16872-16877 (1992).Applicant
• Theys et al., “Tumor-specific gene delivery using genetically engineered bacteria,” Curr Gene Ther 3(3): 207-221 (2003).Applicant
• Timiryasova et al., “Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper,” BioTechniques 31: 534-540 (2001).Applicant
• Tjuvajev et al., “Imaging the Expression of Transfected Genes in Vivo,” Cancer Res. 55(24): 6126-6132 (1995).Applicant
• Tjuvajev et al., “Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET™) for diagnostic imaging,” J. Controlled Release, 74: 313-315 (2001).Applicant
• Tlaskalova-Hogenova, “Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases,” Immunol Lett. 93(2-3):97-108 (2004).Applicant
• Torres et al., “Haem iron-transport system in enterohaemorrhagic Escherichia coli O157:H7” Molecular Microbiol. 23(4):825-833 (1997).Applicant
• Toso et al, “Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma,” J Clin Oncol. 20(1):142-52 (2002).Applicant
• Tsung, K. et al., “Immune Response Against Large Tumors Eradicated by Treatment with Cyclophosphamide and IL-12,” J. Immunol., 160: 1369-1377 (1998).Applicant
• Ukena et al., “The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1,” BMC Med. Genetics 6:43 (2005).Applicant
• Vaughan et al., “Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches,” FEMS Microbiol Rev. 29(3):477-90 (2005).Applicant
• Vento, S. and F. Cainelli, “Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment,” Lancet, 4: 595-604 (2003).Applicant
• Venturi et al. “Gene regulation of siderophore-mediated iron acquisition in Pseudomonas: not only the Fur repressor,” Mol. Microbiol. 17(4): 603-610 (1995).Applicant
• Verma et al., “Gene therapy- promises, problems and prospects” Nature 389:239-242 (1997).Applicant
• Visca, “Iron transport and regulation, cell signalling and genomics: lessons from Escherichia coli and Pseudomonas” Mol Microbiol. 45(5):1177-90 (2002).Applicant
• Wade et al., “Gene induction during differentiation of human pulmonary type II cells in vitro,” Am J. Respir. Cell. Mol. Biol. 34:727-737 (2006).Applicant
• Wahl, R., et al., “Improved radioimaging and tumor localization with monoclonal F(ab′)2,” Journal of Nuclear Medicine, 24:316-325, (1983).Applicant
• Waidner et al. “Essential role of Ferritin Pfr in Helicobacter pylori Iron Metabolism and Gastric Colonization” Infec. Immun. 70(7): 3923-3929 (2002).Applicant
• Wandersman and Delepelaire. “Bacterial iron sources: From siderophores to hemophores” Ann. Rev. Microbiol. 58: 611-647 (2004).Applicant
• Wang Y. et al., “A study of protein-protein interactions in living cells using luminescence resonance energy transfer (LRET) from Renilla luciferase to Aequorea GFP,” Mol Gen Genet. 264(5):578-87 (2001).Applicant
• Watson et al., “Molecular Biology of the Gene,” The Benjamin/Cummings Publishing Co., 4:224 (1987).Applicant
• Wehkamp et al., “NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium,” Infect. Immun. 72:5750 (2004).Applicant
• Weissleder et al. “Drug targeting in magnetic resonance imaging,” Magnetic Resonance Quarterly. 8(1):55-63 (1992).Applicant
• Weissleder et al., “Molecular imaging,” Radiol 219:316-333 (2001).Applicant
• Weissleder, T. et al., “In vivo magnetic resonance imaging of transgene expression,” Nat. Med. 6(3): 351-354 (2000).Applicant
• Welling et al “Radiochemical and biological characteristics of 99mTc-UBI 29-41 for imaging of bacterial infections.” Nucl Med Biol. 29(4):413-22 (2002).Applicant
• Welling et al “Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations.” Eur J Nucl Med. 27(3):292-301 (2000).Applicant
• Weng et al., “HO-1 expression in type II pneumocytes after transpulmonary gene delivery” Am. J. Physiol. Lung Cell Mol. Physol 278:L1273-L1279 (2000).Applicant
• West et al. “Identification of a somatodendritic targeting signal in the cytoplasmic domain of the transferrin receptor.” J Neurosci. 17(16):6038-47 (1997).Applicant
• Westendorf, “Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules,” 43(3):373-84 (2005).Applicant
• Winkelmann, “Microbial siderophore-mediated transport,” Biochem. Soc. Trans. 30(4): 691-696 (2002).Applicant
• Wooldridge and Williams, “Iron uptake mechanisms of pathogenic bacteria,” FEMS Microbiol. Rev. 12(4): 325-348 (1993).Applicant
• Wu et al., “High resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment,” PNSA USA 97(15): 8495-8500 (2000).Applicant
• Xu and Lee, “Display of polyhistidine peptides on the Escherichia coli cell surface by using outer membrane protein C as an anchoring motif,” Appl Environ Microbiol. 65(11):5142-7 (1999).Applicant
• Yamane et al., “Protein traffic for secretion and related machinery of Bacillus subtilis” Biosci. Biotechnol. Biochem. 68(10):2007-2023 (2004).Applicant
• Yan, “Commensal bacteria in the gut: learning who our friends are,” Curr Opin Gastroenterol. 20(6):565-71 (2004).Applicant
• Yang et al., “Ability of Pseudomonas pseudomallei Malleobactin to acquire Transferrin-Bound, Lactoferrin-Bound, and Cell-Derived Iron” Infection and Immunity 61(2):656-662 (1993).Applicant
• Yang et al., “Effects of growth medium composition, iron sources and atmospheric oxygen concentrations on production of luciferase-bacterial magnetic particle complex by a recombinant Magnetospirillum magneticum AMB-1,” Enzyme Microb. Technol. 29: 13-19 (2001).Applicant
• Yongxin et al., “Biomineralization and magnetism of bacterial megnetosomes” Chinese Sci. Bulletin 49(24):2563-2568 (2004).Applicant
• Yoshida et al., “Growth-inhibitory effect of streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor,” Cancer Research 61(16): 6151-6157 (2001).Applicant
• Yu et al., “A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo,” Mol Genet Genomics. 268(2):169-78 (2002).Applicant
• Yu et al., “Optical imaging: bacteria, viruses, and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and metastases in animals,” Anal Bioanal Chem. 377(6):964-72 (2003).Applicant
• Yu Y., “Visualization of molecular and cellular events with green fluorescent proteins in developing embryos: a review,” Luminescence. 18(1):1-18 (2003) Erratum in: Luminescence.18(4):243 (2003).Applicant
• Zhao et al. “Iron and Hydrogen Peroxide Detoxification Properties of DNA-binding Protein from Starved Cells” J. Biol. Chem. 277(31): 27689-27696 (2002).Applicant
• Zhao et al., “Spatial-temporal imaging of bacterial infection and antibiotic response in intact animals,” Proceeding of the National Academy of Sciences 98(17): 9814-9818 (2001).Applicant
• Zheng et al., “Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector,” Oncology Research 12(3):127-135 (2000).Applicant
• Zinn et al. “Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re,” J Nucl Med. 41(5):887-95 (2000).Applicant
• Zinn et al., “Simulataneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging,” Nuclear Medicine and Biology 28(2):135-144 (2001).Applicant
• ATCC Accession No. 59324 (accessed on Jan. 4, 2005) (2 pages).Applicant
• ATCC Accession No. 59325 (accessed on Jan. 4, 2005) (2 pages).Applicant
• Baaghil et al., “Core formation in Escherichia coli bacterioferritin requires a functional ferroxidase center,” Biochemistry 42(47):14047-14056 (2003).Applicant
• Bach-Gansmo et al., “Abdominal MRI using a negative contrast agent,” Br. J. Radiol. 66(785):420-425 (1993).Applicant
• Balbas, P. and F. Bolivar, “Back to basics: pBR322 and protein expression systems in E. coli,”, P. Methods Mol. Biol. 267: 77-90 (2004).Applicant
• Bassi et al., “Expression of single chain antibodies (ScFvs) for c-myc oncoprotein in recombinant Escherichia coli membranes by using the ice-nucleation protein of Pseudomonas syringae,” Biotechnol. Prog. 16(4):557-563 (2000).Applicant
• Bauminger et al., “Stages in iron storage in the ferritin of Escherichia coli (EcFtnA): analysis of Mössbauer spectra reveals a new intermediate,” Biochemistry. 38(24):7791-7802 (1999).Applicant
• Bianco, A., “Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications,” J. Chemother. 16 (Suppl 4):52-54 (2004).Applicant
• Biffi et al., “Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line,” Nutr Cancer. 28(1):93-99 (1997).Applicant
• Brader et al., “Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging,” Clin. Cancer Res. 14(8):2295-2302 (2008).Applicant
• Brock et al., “Relative availability of transferrin-bound iron and cell-derived iron to aerobactin-producing and enterochelin-producing strains of Escherichia coli and to other microorganisms,” Infection and Immunity 59(9):3185-3190 (1991).Applicant
• Butler et al., “Marine siderophores and microbial iron mobilization,” Biometals 18:369-374 (2005).Applicant
• Camaj et al., “Ligand-mediated protection against phage lysis as a positive selection strategy for the enrichment of epitopes displayed on the surface of E. coli cells,” Biol. Chem. 382:1669-1677 (2001).Applicant
• Certified English translation of DE 102 09 958 entitled “The use of Escherichia coli as antiphlogistic,” published Sep. 25, 2003, Inventor: Hibi et al., (10 pages).Applicant
• Certified English translation of J. Stritzker and A. Szalay, “E. coli Nissle 1917: Vom Kriegsveteran weiterentwickelt zum aktiven Kämpfer gegen Tumoren? [E. coli Nissle 1917: From War Veteran to Genetically-Directed Tumor Fighter” GenomXpress, 4.07, 12-14. (2007).Applicant
• Chiancone et al., “Iron and proteins for iron storage and detoxification,” Biometals. 17(3):197-202 (2004).Applicant
• Dale et al., “Involvement of SirABC in Iron-Siderophore Import in Staphylococcus aureus,” J. Bacteriol. 186(24):8356-8362 (2004).Applicant
• Eck et al., “Gene-Based Therapy” Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101 (1996).Applicant
• Ellerby et al., “Anti-cancer activity of targeted pro-apoptotic peptides,” Nat. Med. 5(9):1032-1038 (1999).Applicant
• Emens, L. and N. Davidson, “Trastuzumab in breast cancer,” Oncology 18(9):1117-1128 (2004).Applicant
• Fuangthong et al., “Recognition of DNA by Three Ferric Uptake Regulator (Fur) Homologs in Bacillus subtilis,” J. Bacteriol. 185(21):6348-6357 (2003).Applicant
• Genco, C. and W. Dixon, “Emerging strategies in microbial haem capture,” Mol. Microbiol. 39:1-11 (2001).Applicant
• Gorecki, A., “Prospects and problems of gene therapy: an update,” Expert Opin. Emerging Drugs 6(2):187-198 (2001).Applicant
• Grabherr and Bayer, “Impact of targeted vector design on Co/E1 plasmid replication,” Trends Biotechnol. 20(6): 257-260 (2002).Applicant
• Grove, A. and S. Wilkinson, “Differential DNA binding and protection by dimeric and dodecameric forms of the ferritin homolog Dps from Deinococcus radiodurans,” J. Mol. Biol. 347(3):495-508 (2005).Applicant
• Guo et al., “Vaccinia as a vector for gene delivery,” Expert Opin Biol Ther 4(6):901-917 (2004).Applicant
• Izuhara et al., “Cloning and sequencing of an Escherichia coli K12 gene which encodes a polypeptide having similarity to the human ferritin H subunit,” Mol. & Gen. Genet. 225:510-513 (1991).Applicant
• Jeong et al., “Cell surface display of salmobin, a thrombin-like enzyme from Agkistrodon halys venom on Escherichia coli using ice nucleation protein,” Enzyme Microb. Technol. 28:155-160 (2001).Applicant
• Jung, Y. and Y. Lee, “RNases in ColE1 DNA metabolism,” Mol. Biol. Rep. 22(2-3):195-200 (1995-1996).Applicant
• Jung et al., “Expression of carboxymethylcellulase on the surface of Escherichia coli using Pseudomonas syringae ice nucleation protein,” Enzyme Microb Technol. 22(5):348-354 (1998).Applicant
• Jung et al., “Surface display of Zymomonas mobilis levansucrase by using the ice-nucleation protein of Pseudomonas syringae,” Nat. Biotechnol. 16:576-580 (1998).Applicant
• Kanda et al., “Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system,” J. Virol. 78(13):7004-7015 (2004).Applicant
• Khalil et al., “Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria,” Chembiochem. 7(4):678-683 (2006).Applicant
• Kok et al., “Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection,” Cancer Biotherapy & Radiopharmaceuticals 20(3):310-315 (2005).Applicant
• Langridge, W. and A. Szalay, “Bacterial and coelenterate luciferases as reporter genes in plant cells,” Chapter 37 in Methods Mol Biol. 82:385-396 (1998).Applicant
• Lecointre et al., “Escherichia coli molecular phylogeny using the incongruence length difference test,” Mol. Biol. Evol. 15(22):1685-1695 (1998).Applicant
• Lee et al., “Microbial cell-surface display,” Trends Biotechnol. 21:45-52 (2003).Applicant
• Levi et al., “Characterization of human ferritin H chain synthetized in Escherichia coli,” Gene 51(2-3):269-274 (1987).Applicant
• Liebregts et al., “Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model,” Neurogastroenterology and Motility 17(3):410-414 (2005).Applicant
• Liu et al., “A highly efficient recombineering-based method for generating conditional knockout mutations,” Genome Res. 13(3):476-484 (2003).Applicant
• Lu et al., “Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions,” Biotechnology (NY) 13: 366-372 (1995).Applicant
• Marshall et al., “Combinatorial chemistry of metal-binding ligands,” Adv. Supramolecular Chem. 8:174-243 (2002).Applicant
• Nagai et al., “A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications,” Nat. Biotechnol. 20(1):87-90 (2002).Applicant
• Nguyen, A. and P. Daugherty, “Evolutionary optimization of fluorescent proteins for intracellular FRET,” Nat Biotechnol. 23(3):355-360 (2005).Applicant
• Papinutto et al., “Structure of two iron-binding proteins from Bacillus anthracis,” J. Biol. Chem. 277(17):15093-15098 (2002).Applicant
• Penfold et al., “Isolation, characterisation and expression of the bacterioferritin gene of Rhodobacter capsulatus,” FEMS Microbiol Lett. 139(2-3):143-148 (1996).Applicant
• Rong et al., “Engineering large fragment insertions into the chromosome of Escherichia coli,” Gene. 336(1):73-80 (2004).Applicant
• Schwyn, B. and B. Neilands, “Universal chemical assay for the detection and determination of siderophores,” Anal. Biochem. 160:47-56 (1987).Applicant
• Shaner et al., “A guide to choosing fluorescent proteins,” Nat Methods. 2(12):905-909 (2005).Applicant
• Shapiro, J. “Changes in gene order and gene expression,” Natl. Cancer Inst. Monogr. 60: 87-110 (1982).Applicant
• Shimazu et al., “Cell surface display of organophosphorus hydrolase using ice nucleation protein,” Biotechnol. Prog. 17:76-80 (2001).Applicant
• Shine, J. and L. Dalgarno, “Determinant of cistron specificity in bacterial ribosomes,” Nature 254(5495):34-38 (1975).Applicant
• Shkrob et al., “Far-red fluorescent proteins evolved from a blue chromoprotein from Actinia equine,” Biochem J. 392(Pt 3):649-654 (2005).Applicant
• Smith, J., “The Physiological Role of Ferritin-Like Compounds in Bacteria,” Crit. Rev. Microbiol. 30(3):173-185 (2004).Applicant
• Soghomonyan et al., “Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK,” Cancer Gene Ther. 12(1):101-108 (2005).Applicant
• Stritzker, J. and A. Szalay, “E. coli Nissle 1917: Vom Kriegsveteran weiterentwickelt zum aktiven Kämpfer gegen Tumoren? [E. coli Nissle 1917: From War Veteran to Genetically-Directed Tumor Fighter” GenomXpress, 4.07, 12-14. (2007).Applicant
• Stritzker et al., “Evaluation of an in vivo gene induction system in infected tumor-bearing mice,” Proceedings of the 14th International Symposium on Bioluminescence & Chemiluminescence: Chemistry, Biology and Applications. World Scientific:Singapore: 205-208 (2007).Applicant
• Vellanoweth, R., Translation and its regulation. In: Sonenshein AL, Hoch JA, Losick R (eds.) Bacillus subtilis and Other Gram Positive Bacteria; Biochemistry, Physiology and Molecular Genetics. American Society for Microbiology, Washington, DC, pp. 699-711 (1993).Applicant
• Vieira, J. and J. Messing, “Production of single-stranded plasmid DNA,” Methods Enzymol. 153:3-11 (1987).Applicant
• Wang et al., “Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging,” Eur. Radiol. 11(11):2319-2331 (2001).Applicant
• Weissleder et al., “Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging,” Radiology 175:489-493 (1990).Applicant
• Wood et al., “Introduction to beetle luciferases and their applications,” J. Biolumin. Chemilumin. 4(1):289-301 (1989).Applicant
• Yu et al., “Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins,” Nat Biotech. 22(3): 313-320 (2004).Applicant
• Yu et al., “Examinations of bacterium-mediated detection of tumors in mice models”. In: Proceedings of the 14th International Symposium on Bioluminescence & Chemiluminescence: Chemistry, Biology and Applications. World Scientific: Singapore: 209-212 (2007).Applicant
• Zeth et al., “Iron-oxo clusters biomineralizing on protein surfaces: Structural analysis of Halobacterium salinarum DpsA in its low- and high-iron states,” Proc. Natl. Acad. Sci. 101(38):13780-13785 (2004).Applicant
• Zhang et al., “Eradication of solid human tumors in nude mice with an intravenously injected light emitting oncolytic vaccinia virus”, Cancer Res. 67(20):10038-10046 (2007).Applicant
• International Preliminary Report on Patentability, issued Jan. 29, 2009, in connection with International Patent Application Serial No. PCT/US2007/015829.Applicant
• International Search Report and Written Opinion (corrected version), issued Jan. 13, 2009, in connection with International Patent Application Serial No. PCT/US2007/015829.Applicant
• International Search Report and Written Opinion, issued Sep. 11, 2008, in connection with International Patent Application No. PCT/US2007/015829.Applicant
• Kruis, W., “Review article: antibiotics and probiotics in inflammatory bowel disease,” Aliment. Pharmacol. Ther. 20(Suppl 4):75-78 (2004).Applicant
• Loessner et al., “Drug-inducible remote control of gene expression by probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of mice,” Microb. Infect. 11(14-15):1097-1105 (2009).Applicant
• Loessner et al., “Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo,” Cell. Microbiol. 9(6):1529-1537 (2007).Applicant
• Meighen et al., “Molecular biology of bacterial bioluminescence,” Microbiol. Rev. 55(1):123-142 (1991).Applicant
• Office Action, issued Mar. 19, 2009, in connection with U.S. Appl. No. 11/827,518.Applicant
• Stritzker et al., “Prodrug converting enzyme gene delivery by L. monocytogenes,” BMC Cancer 8:94 (2008).Applicant
• Westphal et al., “Containment of tumor-colonizing bacteria by host neutrophils,” Cancer Res. 68(8):2952-2960 (2008).Applicant
• Yu et al., “Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria” Biotechnology and Bioengineering 100(3), 567-578 (2008).Applicant